xmt-2056
·Code: XMT-2056
xmt-2056: developed by 1 company · 1 clinical trial tracked.
xmt-2056 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect xmt-2056 to MRSN; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could xmt-2056 → MRSN affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
HER2-expressing advanced or recurrent solid tumors, including breast, gastric, colorectal and non-small cell lung cancers
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Mersana Therapeutics, Inc. (MRSN) HER2-expressing advanced or recurrent solid tumors, includin… | Phase 1 |
Clinical Trials (1)
A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2
Primary endpoint: Frequency of dose-limiting toxicities (DLTs) associated with XMT-2056 during the first cycle of treatment (Dose Escalation)
Interventionalopen57 targetStarted 2023-01Completion 2026-0514 sites · United StatesDay One Biopharmaceuticals, Inc.
Frequently asked questions
Who is developing xmt-2056?
xmt-2056 is being developed by Mersana Therapeutics, Inc..
How many clinical trials involve xmt-2056?
BioSniper tracks 1 clinical trial involving xmt-2056.